JBIO · Jade Biosciences, Inc.

Jade Biosciences reported first quarter 2026 financial results showing increased operating expenses driven by pipeline advancement. Research and development expenses rose to $36.1 million from $20.0 million in Q1 2025, primarily due to higher chemistry, manufacturing, controls, clinical activities, and personnel costs as the company expands its internal R&D capabilities. General and administrative expenses increased to $7.4 million from $3.4 million, reflecting infrastructure buildout and higher personnel-related costs. This resulted in a net loss of $40.4 million, up from $38.2 million year-over-year, with diluted EPS of $(0.57) for common stockholders. The balance sheet remains strong with $311.3 million in cash, cash equivalents, and investments as of March 31, 2026, providing runway into the first half of 2028 based on current plans. CEO Tom Frohlich highlighted the transition to focused clinical execution, with upcoming Phase 1 biomarker data for lead candidate JADE101, a selective anti-APRIL antibody for IgA nephropathy, to be presented at the 63rd European Renal Association Congress. This data will inform dosing for the Phase 2 trial starting Q2 2026, with interim results in 2027. JADE201, a half-life extended afucosylated anti-BAFF-R antibody, and JADE301, an undisclosed program, are both on track for Phase 1 initiations in Q2 2026 and H1 2027, respectively. Leadership changes include the appointment of Edward R. Conner, M.D., as CMO to oversee clinical development and the promotion of Dr. Andrew King to President, R&D, strengthening execution capabilities across the autoimmune disease-focused pipeline.